European takeover of Curevac, as announced by its founder, signals a positive development for the continent.
======================================================================================
In a significant move for Europe's pharmaceutical industry, BioNTech has completed the acquisition of CureVac for approximately $1.25 billion in shares as of July 2025 [1][3]. This merger aims to strengthen BioNTech's research, development, and commercialization capabilities, particularly in oncology and mRNA technologies.
The German state-owned bank KfW, acting on behalf of the federal government, has signed a public tender and support agreement with BioNTech to fully back the acquisition financially [4]. This government backing underscores the strategic importance of this deal for Europe’s biotech sovereignty and innovation capacity.
The takeover consolidates two leading mRNA technology companies, enhancing Europe’s competitive position in biotechnology and pharmaceutical innovation globally. The merger is expected to boost BioNTech’s oncology pipeline and broaden its mRNA platform applications beyond COVID-19 vaccines, potentially accelerating medical advances within Europe [1][5].
The acquisition also marks strategic shifts within BioNTech, with the company's chief strategy officer resigning shortly after the announcement [2]. This move could signal the integration of CureVac's assets and technology into BioNTech's operations.
The merger creates a strong European rival to the US-based giant Moderna in the realm of mRNA technology. The potential of mRNA technology is far from exhausted, and not to be underestimated are the technological know-how and experience of CureVac in this field.
The research landscape in Tübingen, where both BioNTech and CureVac are based, could also benefit from this takeover, potentially fostering further innovation and collaboration.
It's worth noting that Ingmar Hoerr, founder of CureVac, views the planned takeover of CureVac by BioNTech as a positive sign for Europe. However, patent disputes between the two companies had unnecessarily hindered progress in the past, but with the takeover, these disputes are expected to end [6].
This article is brought to you without advertisements. To subscribe to topics and save articles, a Staatsanzeiger subscription is required.
Ingmar Hoerr, who stepped down from his post at CureVac in March 2020 following a brain hemorrhage, and in 2021, he withdrew his planned candidacy for the supervisory board due to health problems [7].
As forces are bundled in the future following the takeover, it remains to be seen how this merger will shape the future of pharmaceutical research and innovation in Europe.
You can share this article via email, WhatsApp, Facebook, Twitter, Xing, and LinkedIn.
The German state-owned bank KfW, on behalf of the federal government, has provided financing for the merger of The Agency (BioNTech) and CureVac, signifying a significant investment in the finance sector for business and technology advancements within Europe.
With the merger, The Agency anticipates a boost in its oncology pipeline and the broadening of its technology applications, potentially propelling medical and technological innovations across Europe.
